Vicept Therapeutics Announces Positive Results from a Second Phase II Study of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea) - Drugs.com MedNews
Links shared publicly online about this topic.
- 354total visits
Vicept Therapeutics Announces Positive Results from a Second Phase II Study of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea) - Drugs.com MedNews
-Both Phase II studies achieve statistically significant improvement in primary endpoint of facial redness associated with rosacea- -Safety profile similar to p
View full resource at drugs.com
Most Recently Shared on April 19, 2011 at 2:22 pm By:
Vicept Therapeutics Announces Positive Results from a Second Phase II Study of V-101 for the Treatment of ... http://bit.ly/hMEemk #drug
Advertisement
